

**Filed PCT/PTO 12 APR 2002**

**#3**

Attorney Docket No. 3229/1/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	)	
	)	
GARY S. JACOB	)	
and	)	EXAMINER:
RAYMOND A. DWEK	)	
	)	
SERIAL NUMBER: 10/031,767	)	
	)	
FILED: JAN. 23, 2002	)	GROUP ART UNIT:
	)	
TITLE: COMBINATION DRUG	)	
THERAPY FOR GLYCOLIPID	)	
STORAGE DISEASES	)	

---

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.97-1.98


Hon. Commissioner of Patents  
Washington, D. C. 20231

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, the attached listed patents and publications are cited to the Examiner as being information, which in the good faith judgment of the inventors and the undersigned attorney, might be material to the patentability of the subject matter claimed in the above-identified application. This statement applies only to such patents and publications which the inventors and the undersigned attorney have in fact reviewed or considered. However, none of this information or other information reviewed or considered by the inventors or the undersigned attorney is believed to constitute a *prima facie* case of unpatentability.

Pursuant to MPEP §609, the cited patents and publications are listed on the attached Form PTO-1449.

Foreign language Document R is included in this IDS since it was cited in the International Search Report from the European Patent Office in a counterpart application of the parent of the present application. No translation of Document R was provided with the International Search Report nor is a translation otherwise available to the undersigned attorney. As presently understood by the undersigned attorney, the relevance of Document R is that it discloses derivatives of 3,4,5-trihydroxypiperidine, methods of their preparation and their uses. The disclosed derivatives include the alkyl derivatives having from 1-30 carbon atoms. No biological data for the derivatives is disclosed so far as can be ascertained by the undersigned attorney but the abstract on the title page describes their use as mannosidase inhibitors. On page 22, combinations with amylase inhibitors are mentioned but there does not appear to be any mention or suggestion of applicant's claimed combination with glucocerebrosidase enzymes for treatment of Gaucher's disease and the like glycolipid storage diseases. As presently understood by the undersigned attorney, Document R is believed to be no more relevant, or less relevant, than the other documents cited by applicant.



---

Scott J. Meyer  
Registration No. 25,275

SJM/mr

April 8, 2002